Palvella Therapeutics, Inc. Payments of Merger Related Costs, Financing Activities
Palvella Therapeutics, Inc. (PVLA) reported Payments of Merger Related Costs, Financing Activities of $0 for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsOfMergerRelatedCostsFinancingActivities · last filed 2026-08-04
- Palvella Therapeutics, Inc. payments of merger related costs, financing activities for the quarter ending 2026-06-30 was $0.00.
- Palvella Therapeutics, Inc. payments of merger related costs, financing activities for the quarter ending 2026-03-31 was $0.00, a 100.00% decline year-over-year.
- Palvella Therapeutics, Inc. payments of merger related costs, financing activities for the quarter ending 2025-12-31 was $0.00, a 100.00% decline year-over-year.
- Palvella Therapeutics, Inc. payments of merger related costs, financing activities for the quarter ending 2025-09-30 was $0.00.
- Palvella Therapeutics, Inc. payments of merger related costs, financing activities for fiscal 2025 was $1.27M, a 48.71% decline from fiscal 2024.
- Palvella Therapeutics, Inc. payments of merger related costs, financing activities for fiscal 2024 was $2.47M.
- Palvella Therapeutics, Inc. payments of merger related costs, financing activities for fiscal 2023 was $0.00.
| Period end | Payments of Merger Related Costs, Financing Activities 3 month | Payments of Merger Related Costs, Financing Activities 6 month | Payments of Merger Related Costs, Financing Activities 9 month | Payments of Merger Related Costs, Financing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $0.00 10-Q · filed 2026-08-04 | $0.00 derived: sum of 3 quarters · filed 2026-08-04 | $0.00 derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | $0.00 10-Q · filed 2026-05-07 | $0.00 derived: sum of 2 quarters · filed 2026-05-07 | $0.00 derived: sum of 3 quarters · filed 2026-05-07 | $0.00 derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $0.00 derived: sum of 2 quarters · filed 2026-03-31 | $0.00 derived: sum of 3 quarters · filed 2026-08-04 | $1.27M 10-K · filed 2026-03-31 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $0.00 derived: sum of 2 quarters · filed 2026-08-04 | $1.27M 10-Q · filed 2025-11-12 | $3.74M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $1.27M 10-Q · filed 2026-08-04 | $3.74M derived: sum of 3 quarters · filed 2026-08-04 | $3.74M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | $1.27M 10-Q · filed 2026-05-07 | $3.74M derived: sum of 2 quarters · filed 2026-05-07 | $3.74M derived: sum of 3 quarters · filed 2026-05-07 | $3.74M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $2.47M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $2.47M derived: sum of 2 quarters · filed 2026-03-31 | $2.47M derived: sum of 3 quarters · filed 2026-03-31 | $2.47M 10-K · filed 2026-03-31 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $0.00 derived: sum of 2 quarters · filed 2025-11-12 | $0.00 10-Q · filed 2025-11-12 | |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $0.00 10-Q · filed 2025-08-14 | ||
| 2024-03-31 | $0.00 10-Q · filed 2025-05-15 | |||
| 2023-12-31 | $0.00 10-K · filed 2025-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |